IL201834A0 - Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor - Google Patents

Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Info

Publication number
IL201834A0
IL201834A0 IL201834A IL20183409A IL201834A0 IL 201834 A0 IL201834 A0 IL 201834A0 IL 201834 A IL201834 A IL 201834A IL 20183409 A IL20183409 A IL 20183409A IL 201834 A0 IL201834 A0 IL 201834A0
Authority
IL
Israel
Prior art keywords
reversible
intravenous
inhibitor
acting
direct
Prior art date
Application number
IL201834A
Other languages
English (en)
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of IL201834A0 publication Critical patent/IL201834A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL201834A 2007-05-02 2009-10-29 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor IL201834A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
IL201834A0 true IL201834A0 (en) 2010-06-16

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201834A IL201834A0 (en) 2007-05-02 2009-10-29 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Country Status (17)

Country Link
US (2) US20090048216A1 (https=)
EP (1) EP2079464A2 (https=)
JP (1) JP2010526101A (https=)
KR (1) KR20100029746A (https=)
CN (1) CN101795682A (https=)
AU (1) AU2008247483A1 (https=)
BR (1) BRPI0811476A2 (https=)
CA (1) CA2686203A1 (https=)
CO (1) CO6241104A2 (https=)
EA (1) EA200901473A1 (https=)
EC (1) ECSP099778A (https=)
GT (1) GT200900284A (https=)
IL (1) IL201834A0 (https=)
MA (1) MA31663B1 (https=)
MX (1) MX2009011843A (https=)
TN (1) TN2009000451A1 (https=)
WO (1) WO2008137753A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1951254E (pt) * 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
CA2678492A1 (en) * 2007-03-06 2008-09-12 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
MX2011006995A (es) * 2008-12-30 2011-09-27 Thrombologic Aps Metodos para identificar pacientes criticamente enfermos en riesgo incrementado de desarrollar nsuficiencia organica y compuestos para el tratamiento de la misma.
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2633857B1 (en) * 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646827A1 (en) 2010-12-01 2013-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
PT1951254E (pt) 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas

Also Published As

Publication number Publication date
JP2010526101A (ja) 2010-07-29
KR20100029746A (ko) 2010-03-17
US20090048216A1 (en) 2009-02-19
CO6241104A2 (es) 2011-01-20
GT200900284A (es) 2012-01-31
WO2008137753A3 (en) 2009-02-12
CN101795682A (zh) 2010-08-04
EP2079464A2 (en) 2009-07-22
EA200901473A1 (ru) 2010-06-30
US20120009172A1 (en) 2012-01-12
MX2009011843A (es) 2010-04-22
TN2009000451A1 (en) 2011-03-31
BRPI0811476A2 (pt) 2014-11-04
AU2008247483A1 (en) 2008-11-13
MA31663B1 (fr) 2010-09-01
WO2008137753A2 (en) 2008-11-13
CA2686203A1 (en) 2008-11-13
ECSP099778A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
IL201834A0 (en) Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
TWI561183B (en) Oral care implement
SI2185198T1 (sl) Inhibitorji LOX in LOXL2 ter njihova uporaba
LT2807926T (lt) Tetraciklino junginio druskos ir polimorfai
IL212841A0 (en) Dpp iv inhibitor formulations
GB0625659D0 (en) Therapeutic compounds and their use
PL2957278T3 (pl) STABILNA KOMPOZYCJA ZAWIERAJĄCA PTHrP ORAZ JEJ ZASTOSOWANIA
GB0703438D0 (en) Preventing spread of infection
PL2173345T3 (pl) Doustna formulacja metadoksyny
IL213694A0 (en) Melanin production inhibitor compounds and compositions comprising the same
AP2627A (en) New form of administration of racecadotril
GB0710439D0 (en) Oral dosage form
IL202765A0 (en) Pharmaceutical combination of nsaid and prostaglandin compound
ZA201103752B (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
PL2271348T3 (pl) Doustny preparat związków tetracyklinowych w postaci tabletki
EP2195316A4 (en) ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF
IL228484A0 (en) 2-mmp and/or 9-mmp inhibitors
PL2046268T3 (pl) Kompozycja do pielęgnacji jamy ustnej
HK1131567A (en) Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
GB2453072B (en) Oral care compositions
GB0622479D0 (en) Novel salts and their therapeutic use
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB2453071B (en) Oral care compositions
IL196265A0 (en) A zipper system with 3 sets of teeth
GB0605257D0 (en) Medic aware bracelet